Тамоксифен

Quick links

Choose a section

Quick links to important sections

Advertisements

Тамоксифен

Selected form

Advertisements

Overview of Тамоксифен

Quick Facts

Property Description
Active ingredient Tamoxifen citrate
Form Oral Tablets, Oral Liquid
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
Common use Hormone-sensitive condition modulation
Origin Synthetic (Nonsteroidal Antiestrogen Compound)

Тамоксифен: A Selective Estrogen Receptor Modulator (SERM)

Тамоксифен is a synthetic organic compound classified as a Selective Estrogen Receptor Modulator (SERM), which is a specialized type of nonsteroidal antiestrogen medication used to modulate the body's hormonal systems. As an Antineoplastic Agent, its general purpose is to interfere with the activity of estrogen, a hormone that can stimulate cell growth in certain tissues. The clinical utility of this SERM class relates to its role in hormone-sensitive contexts.

The core identity of Тамоксифен, which belongs to the triphenylethylene chemical structure, is defined by its role as a SERM, meaning it exhibits tissue-selective action. This differentiates it from older therapies by acting as an Estrogen Receptor antagonist (a blocker) in specific tissues, while simultaneously demonstrating a partial agonist (estrogen-mimicking) effect in other areas of the body. The medication functions by blocking estrogen's effects on certain cancer cells, which is central to its therapeutic application as an Anti-estrogen compound.

What is the Composition and Form of Тамоксифен?

The primary active ingredient in the medicine is Tamoxifen, typically supplied as the salt form, Tamoxifen citrate. Тамоксифен is a single active ingredient product designed for oral route of administration. The medication is commonly available as solid tablets and may also be found in oral liquid form (such as Soltamox).

Notably, Тамоксифен functions as a prodrug, meaning the substance administered is converted by the body into more powerful active metabolites, like endoxifen, which are ultimately responsible for the therapeutic effect of competitive binding to Estrogen Receptors. The substance is metabolized into these active forms to achieve its intended effect in the body.

Regulatory References

  1. Tamoxifen Citrate - NCI
  2. Tamoxifen - StatPearls - NIH
Advertisements

What side effects are possible with Тамоксифен?

Official Safety Profile Overview

This section summarizes the adverse reactions and safety information for tamoxifen as documented in authoritative government regulatory sources (e.g., FDA, EMA). It outlines established risks based on frequency, serious nature, and body system involvement.

Serious Adverse Reactions

Regulatory documents highlight several serious and potentially life-threatening risks. These typically require immediate medical attention and include:

  • Thromboembolic Events: Formation of blood clots, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and stroke.
  • Uterine Malignancies: Increased risk of cancers of the uterus, including endometrial carcinoma and uterine sarcoma. This risk is noted to increase with the duration of use.
  • Hepatotoxicity: Cases of liver damage, including cholestasis and hepatic failure (sometimes fatal).
  • Severe Skin Reactions: Rare but serious reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Ocular Toxicity: Visual disturbances, including cataracts, retinopathy, and optic neuropathy.

Frequency-Classified Adverse Reactions

The following is a summary of commonly documented side effects:

Classification Examples of Reactions
Very Common (ge 1/10) Hot flashes, nausea, fluid retention (edema), vaginal discharge, and vaginal bleeding.
Common (ge 1/100 to < 1/10) Fatigue, rash, headache, dizziness, visual disturbances, gastrointestinal upset, changes in liver enzymes, and endometrial polyps.

Safety Restrictions and Context

Tamoxifen is contraindicated during pregnancy due to the risk of fetal harm, and should not be used while breastfeeding. Caution is advised in patients with pre-existing conditions such as a history of thromboembolic disease or hypertriglyceridemia. Concomitant use with certain medications, such as coumarin-type anticoagulants, requires close monitoring due to increased risk of bleeding.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose is based strictly on descriptions provided in official government regulatory documents.

Documented Overdose Manifestations

Symptoms officially documented in regulatory summaries following over-exposure include uncontrollable shaking, dizziness, and unsteadiness or difficulty walking. Other clinical presentations cited in high-dose scenarios are nausea, vomiting, hot flushes, and vaginal bleeding. High cumulative doses have been associated with specific toxicities, including ocular disorders such as reversible retinopathy and macular oedema. Physiological findings such as QT prolongation, a change in heart rhythm, have also been reported in the context of higher-than-approved doses.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required for any severe or life-threatening manifestations, as mandated by regulatory guidance. Patients must call emergency services immediately if a victim has experienced a seizure, collapse, trouble breathing, or cannot be awakened. These conditions define the threshold for urgent intervention.

Supportive Management

Regulatory documentation confirms that no specific antidote for overdosage is known. Consequently, management is symptomatic and supportive. Procedural interventions, such as inducing emesis or gastric lavage, may be indicated in cases of massive overdosage. Accidental ingestion by a child is noted as a specific circumstance that may warrant gastric emptying.

Advertisements

Therapeutic Uses of Тамоксифен

What Тамоксифен treats: Main Uses and Benefits

The therapeutic scope of Tamoxifen is commonly used across conditions presenting with systemic or localized discomfort where cell growth is characterized by physiological activity linked to estrogen. It may be part of symptomatic management in clinical settings that involve acute or disruptive symptom patterns related to hormone-sensitive disease.

The medication is used for managing Estrogen Receptor-Positive (ER+) breast cancer in various stages and is relevant for easing the risk of recurrence after primary intervention. This approach is applied in addressing conditions like severe gynecomastia and is considered relevant for individuals at high risk of developing the disease. This use contributes to long-term outcomes and helps improve day-to-day comfort by lowering the chance of the disease developing or returning. The overall benefit is that the treatment supports the patient by assisting with disease control, and may assist with managing symptoms in advanced contexts.

Quick Facts: Therapeutic Relevance

Category Primary Benefit
Symptom Domain Symptoms related to physical discomfort or tissue strain linked to estrogen.
Use Context Applied in both chronic risk reduction and active disease management settings.
Patient Benefit Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Tamoxifen uses
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Тамоксифен?

Eligibility for Тамоксифен (Tamoxifen) is strictly defined by regulatory authorities based on population, physiological status, and underlying health conditions. This information is derived from official prescribing documents.


Who is Eligible?

  • Adults: Approved for both females (pre- and postmenopausal) and males with Estrogen Receptor-Positive (ER+) breast cancer [FDA Label].
  • Risk Reduction: Indicated for women at high risk of breast cancer or with Ductal Carcinoma In Situ (DCIS) [FDA Label].

Who Must Not Use Tamoxifen? (Contraindications)

Contraindicated Group Condition/Status
Allergy/Sensitivity Known hypersensitivity to the active ingredient or excipients [SmPC].
Pregnancy Contraindicated due to potential fetal harm [SmPC].
Risk Reduction Setting History of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) [FDA Label].
Risk Reduction Setting Concurrent use of warfarin [FDA Label].

Restricted or Not Recommended Use

  • Pediatric Patients: Use is generally not recommended as safety and effectiveness have not been established in children [SmPC].
  • Lactation: Use is not recommended while breastfeeding [SmPC].
  • Women of Childbearing Potential: Must use effective non-hormonal contraception during treatment and for a specified period after the last dose [SmPC].
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic Interactions

The official regulatory profile identifies interactions that affect Tamoxifen’s metabolism. Co-administration with potent CYP2D6 inhibitors, such as Paroxetine or Fluoxetine, should be avoided as they reduce the conversion of Tamoxifen into its active metabolite, Endoxifen, resulting in lower systemic concentrations. Strong CYP3A4 inducers, including Rifampin, also reduce the overall exposure to Tamoxifen and are advised against. This metabolic consideration is further refined by pharmacogenetic data, which notes that individuals classified as CYP2D6 intermediate or poor metabolizers exhibit lower levels of the active metabolite.

Pharmacodynamic Interactions and Restrictions

These interactions reinforce specific risks. The use of Tamoxifen is formally contraindicated in certain patients who require concomitant Warfarin therapy due to the risk of a significant increase in anticoagulant effect. The co-administration of Tamoxifen with Cytotoxic Agents (chemotherapy) is associated with an officially documented increased risk of thromboembolic events.

Other specific regulatory restrictions include the prohibition of combining Tamoxifen with Anastrozole or with Estrogen-containing products, as these combinations may diminish the intended therapeutic effect.

Advertisements

Mechanism of Action

How Tamoxifen Works

Tamoxifen is a Selective Estrogen Receptor Modulator ( SERM), meaning its biological action is determined by a tissue-specific interaction with the Estrogen Receptor ( ER). This action is central to modulating cellular and systemic responses to estrogen, resulting in a complex, dual physiological profile.

Tissue-Selective ER Modulation and Gene Transcription

The drug functions by competitively binding to the ER, but its primary mechanism requires metabolic conversion into the potent metabolite, Endoxifen. This metabolite dictates the subsequent effect by either recruiting co-repressors to block estrogen-driven gene transcription (antagonism) or recruiting co-activators to promote transcription (partial agonism). The resulting suppression of cellular proliferation emerges from the antagonistic action, which suppresses DNA synthesis and arrests the cell cycle in specific estrogen-sensitive cells.

Systemic and Metabolic Pathway Influence

The agonistic action in non-target tissues influences crucial physiological systems, affecting processes beyond cell growth. In the liver, ER agonism results in the modulation of lipid metabolism, affecting HDL cholesterol levels. Concurrently, the modulation of ERs in the bone affects the regulation of bone mineral density, while central antagonism in the hypothalamus disrupts hormonal feedback, leading to the physiological consequence of increased gonadotropin release ( LH/ FSH).

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Tamoxifen

Tamoxifen is exclusively administered via the oral route, available in both tablets (10 mg and 20 mg strengths) and an oral solution. The medication can be consumed with or without food.

Dosing and Scheduling Principles

The standard recommended daily dose for most indications is 20 mg. While a daily dose range of 20 mg to 40 mg may be used, doses exceeding 20 mg per day should be administered in divided doses (e.g., twice daily). Tamoxifen tablets must be swallowed whole, and the oral solution should be measured using the dedicated dispensing device to ensure accuracy.

Usage Principle Official Instruction
Duration of Course Typically five years; may be extended to ten years in the adjuvant setting.
Dosing Frequency Once daily (20 mg) or divided doses (for >20 mg total daily dose).
Missed Dose Rule Skip the missed dose and resume the schedule at the regular time; do not take extra medicine.
Population Rule Use in pediatric patients is generally not recommended.

These usage principles establish a standardized protocol for the medication's intake, defining its oral-only route and specific strength requirements (10 mg or 20 mg). They formalize the long-term commitment required for therapy, clearly stating that the duration is typically measured in years. This structured framework dictates the frequency (once or twice daily) and the exact procedural rules for administration and schedule maintenance.

Advertisements

Recent Clinical Evidence

Тамоксифен: Overview of Clinical Studies


Evidence for use in ER-Positive Breast Cancer Treatment

The primary research for Tamoxifen is centered on large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies explore outcomes in females and males diagnosed with Estrogen Receptor-Positive (ER+) breast cancer. Researchers designed these studies to monitor key outcomes, including overall survival and disease recurrence. Data collected over many years reported measured patterns related to recurrence rates observed in the study populations. However, available research provides limited insight into the full impact of genetic differences on these long-term outcomes.


Evidence for use in Breast Cancer Risk Reduction

Research exploring outcomes related to the incidence of developing breast cancer in high-risk individuals involved large, placebo-controlled RCTs. The primary outcomes examined were the incidence of invasive breast cancer and DCIS. The findings described that patterns of measured incidence were tracked in groups assigned to the medicine compared to control groups. These patterns were observed in groups of both premenopausal and postmenopausal women. Despite the comprehensive nature of these trials, the evidence does not definitively characterize a relationship between the observed patterns in cancer incidence and a concurrent change in all-cause mortality during long-term follow-up.

--ôn

Evidence for use in Other Hormone-Sensitive Conditions

The research base for applications like the management of severe gynecomastia in males generally relies on smaller clinical studies. These studies explored outcomes related to patterns of symptom intensity and changes in specific reproductive markers. The duration of observation in these studies was generally short-term, meaning there is a lack of established long-term outcome data. Findings were mixed or varied across studies, reflecting differences in patient populations and measurement methods used.


What is Still Uncertain About the Research Base

While the research is extensive, certain aspects remain unclear. For example, findings regarding the influence of individual genetic variability on long-term treatment outcomes have been inconsistent, and certainty remains low in this area. Also, long-term effects related to certain non-oncology uses are not fully established.

Key Studies & References

  1. Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years Compared with Stopping at 5 Years: The ATLAS Trial
  2. Tamoxifen - StatPearls (Comprehensive Overview of Indications and Research Base)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Тамоксифен (FAQ)

Q: What is the difference between Tamoxifen and other similar medicines?

The key difference lies in its classification as a Selective Estrogen Receptor Modulator ( SERM). Official documents indicate that Tamoxifen has a mixed, tissue-selective effect. This means it acts as an anti-estrogen (a blocker) in certain tissues, such as the breast, while simultaneously showing an estrogen-like effect (partial agonist) in other areas like the liver and bone.


Q: Can I take Tamoxifen if I already have liver problems?

Caution is generally advised for patients who have existing or a predisposition to compromised hepatic function (liver problems). Regulatory documents contain warnings about the risk of hepatotoxicity (liver damage) associated with the drug. This information is intended to inform discussions with a healthcare provider regarding risk assessment.


Q: Does Tamoxifen affect the ability to get pregnant in the future?

Regulatory guidance indicates that Tamoxifen does not reliably cause infertility. While menstrual cycles may become irregular or stop during therapy, they typically resume after the treatment is completed. Non-hormonal contraception is consistently required throughout the course of treatment and for a specified time afterward, due to the regulatory warning regarding the risk of fetal harm.


Q: Is there data on the long-term consequences of taking Tamoxifen?

Yes, extensive data has been collected over many years from large clinical trials on its use for ER+ breast cancer. Official sources note, however, that the long-term impact of individual genetic differences on outcomes is still being studied. Also, the full long-term effects for applications outside of oncology treatment are not as well-established.


Q: Why do some people use Tamoxifen for non-cancer reasons?

According to regulatory documents, Tamoxifen is officially approved for the reduction of the incidence of breast cancer in certain populations. This indication is intended for women who are considered to be at high risk of developing the disease, as well as for those who have been treated for Ductal Carcinoma In Situ ( DCIS).


Q: Is Tamoxifen a hormonal drug or not?

Official documents classify Tamoxifen as a Selective Estrogen Receptor Modulator ( SERM) and a nonsteroidal antiestrogen. This means it is a type of medicine that functions by modulating the body's hormonal systems. Its primary mechanism involves interfering with the activity of the hormone estrogen in specific tissues.


Q: Are there age restrictions for taking Tamoxifen?

Official guidance states that Tamoxifen is generally not recommended for pediatric patients because its safety and effectiveness have not been established in children. The medication is approved for use in adults, including pre- and postmenopausal women, and men.


Q: Can I drive a car during treatment with Tamoxifen?

Regulatory patient information recommends that individuals use caution when driving or operating machinery. This is because side effects such as fatigue, drowsiness, and visual disturbances have been reported in connection with the drug. Patients are advised to understand their reaction to the medication before attempting these activities.


Q: Can I take Tamoxifen if I have varicose veins?

The medication carries an officially documented increased risk of thromboembolic events (blood clots). Conditions that increase this risk, such as a history of deep vein thrombosis ( DVT), often require a special evaluation by a physician before treatment begins.


Q: What is the 'anti-estrogen' effect of Tamoxifen in simple terms?

The anti-estrogen effect refers to its function as a blocking agent (antagonist) in specific tissues. It works by binding to the Estrogen Receptor and preventing the natural hormone estrogen from stimulating the growth of certain cells. This effect is central to its therapeutic application as a nonsteroidal antiestrogen compound.


Q: Is Tamoxifen chemotherapy?

Official regulatory documents classify Tamoxifen as an antineoplastic hormonal agent and a SERM. It is a form of hormonal therapy, not traditional cytotoxic chemotherapy. Its mechanism is primarily cytostatic (stopping cell division) rather than cytotoxic (killing cells directly).


Q: Can Tamoxifen really affect mood?

According to official safety documents, mood changes are listed as a common adverse reaction associated with the drug. This information is based on the frequency patterns observed in clinical settings and reported to regulatory bodies.


Q: Does Tamoxifen cause weight gain?

While weight gain itself may not always be listed as a frequent side effect, fluid retention (edema) is documented in official safety information as a very common adverse reaction (ge 1/10). Fluid retention is a condition that can result in an increase in body weight.


Q: Do I need to change my diet while taking Tamoxifen?

Official guidelines indicate that the medication can be taken with or without food. Furthermore, some regulatory patient summaries note that there are no known interactions between Tamoxifen and specific foods or drinks that would necessitate a change in diet.


Q: Why must Tamoxifen be taken for several years?

The prolonged duration of treatment, typically five to ten years, is based on the findings of large-scale clinical studies. This length of time is determined to be necessary to achieve the desired long-term reduction in the risk of disease recurrence and to positively influence overall survival patterns.


Q: How can Tamoxifen interact with common pain relievers?

The primary interaction caution is reserved for medications that are strong inhibitors of the CYP2D6 enzyme, which is responsible for converting Tamoxifen to its active form. Most common non-prescription pain relievers are generally considered to have no significant interaction, but all concurrent medications should be disclosed to the prescribing physician to screen for potential interactions.


Q: Is it allowed to take Tamoxifen if I take vitamins?

Official regulatory guidance advises patients to inform their healthcare provider about all concomitant therapy. This includes all prescription and over-the-counter medicines, as well as any vitamins, minerals, or herbal and dietary supplements they may be taking.


Q: What is known about Tamoxifen's interaction with alcohol?

Some regulatory patient information notes that the effect of alcohol on Tamoxifen's efficacy is not known. However, alcohol consumption may potentially increase the frequency or severity of certain common adverse reactions, such as hot flashes.


Q: What happens if I stop taking Tamoxifen?

Regulatory guidance notes that stopping the medication without first consulting a managing physician may impact long-term disease management. The drug's long-term course is critical to the management of recurrence risk as established in clinical trials.


Q: Does Tamoxifen affect sleep?

While official adverse reaction lists may not specifically name sleep disorders like insomnia, commonly reported side effects such as fatigue and hot flashes can potentially disrupt the quality of a patient's sleep.


Q: Are there studies comparing different Tamoxifen dosages?

Regulatory dosing information indicates that doses exceeding 20 mg per day have not been shown to provide additional clinical benefit in the adjuvant setting. This is based on the collected research evidence and patterns of outcome tracked in study populations.


Q: Do I need special tests while taking Tamoxifen?

Regulatory guidelines advise the use of periodic monitoring of certain functions, including regular liver function tests and blood counts. Women without a hysterectomy typically undergo an annual gynecological examination for monitoring purposes.


Q: How often should I visit the doctor during treatment?

Official guidance emphasizes the importance of keeping all scheduled appointments for required tests. Women with an intact uterus are typically advised to undergo an annual gynecological examination as a component of the monitoring protocol.


Q: Are there foods that can enhance or weaken the effect of Tamoxifen?

Some official patient information sources note that there are no known interactions between Tamoxifen and foods or drinks. The drug can be taken regardless of mealtime.


Q: Can Tamoxifen interact with blood pressure medications?

Potential interactions may occur with certain heart and blood pressure medications, particularly those that are known to be strong inhibitors of the CYP2D6 or CYP3A4 enzymes. Patients are advised to inform their physician of all medications taken to allow for screening of these potential interactions.


Q: How can I check if Tamoxifen is working in my case?

The effectiveness of the medication is primarily assessed by the managing physician through periodic monitoring and clinical tests. The drug's therapeutic goal is based on the long-term patterns observed in studies, specifically the reduction in the risk of disease recurrence over many years.

Advertisements

How should Тамоксифен be stored and disposed of?

Official Storage and Disposal Requirements

Tamoxifen (tablets and oral solution) must be stored at room temperature, typically 20 C to 25 C (68 F to 77 F), with tablets not exceeding 30 C. It must be kept in the original container and maintained tightly closed.

Storage Restriction Requirement
Oral Solution Must not be frozen or refrigerated and must be protected from light.
In-Use Stability Oral solution must be discarded 3 months after opening the bottle.
Child Safety Keep the medicine out of the reach and sight of children.

Unused or expired product should be disposed of according to the specific instructions from a pharmacist or local regulatory authority. One official source states no special requirements for disposing of unused tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тамоксифен found in:

A-Z Index: